Navigation Links
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Date:10/1/2008

jective perceptions of hunger and

fullness" will be presented by Nico Pannacciulli, MD, PhD, Sunday,

October 5 at 5:30 p.m. PT (8:30 p.m. ET).

7. Poster 489-P: "Central activation and weight-lowering actions of

AC164209, a peptide hybrid linking a glucagon-like peptide-1 (GLP-1)

receptor agonist and an amylin mimetic" will be presented by Christine

Mack, PhD, Sunday, October 5 at 5:30 p.m. PT (8:30 p.m. ET).

8. Corporate-sponsored symposium: "Emerging Peptide Hormone Therapies for

the Treatment of Obesity: Mechanisms of Action, Clinical Safety and

Efficacy." This medical educational symposium will help healthcare

providers understand the peptide hormone approach to the treatment of

obesity. The event will be chaired by George A. Bray, MD, MACP,

Saturday, October 4 at 7:15 p.m. PT (10:15 p.m. ET). This symposium

is supported by an unrestricted educational grant from Amylin

Pharmaceuticals.

9. Corporate-sponsored symposium: "Reducing CVD Risk: Emerging Science

and Therapeutic Options in the Management of Obesity and Type 2

Diabetes." This medical education symposium will help healthcare

providers understand new science and therapeutic options to reducing

cardiovascular disease risk in the treatment of obesity and type 2

diabetes. The event will be chaired by Robert H. Eckel, MD, Monday,

October 6 at 5:45 p.m. PT (8:45 p.m. ET). This symposium is supported

by an unrestricted educational grant from Amylin Pharmaceuticals and

Eli Lilly and Company.

A full list of all Amylin abstracts being presented at the 2008 Obesity Society meeting is available at: http://www.obesity.org/annualmeeting08/OS_Phoenix08_Final_Program.pdf .

About Obesity


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
3. Critical Pharmaceuticals Enter Sustained Release hGH Arena
4. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
5. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
6. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
7. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
8. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
10. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
11. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... updated its full year 2015 financial guidance and business ... Updated Financial Guidance , Total revenues for ... expected to be between $7.0 and $8.0 million. The Company ... for the remainder of the year, and therefore expects ...
(Date:5/27/2015)... , May 27, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... a member of the Roche Group, announced today a ... for Ventana to ultimately commercialize, a companion diagnostic assay ... The Ventana assay will be used to ... – a chain of natural sugars distributed throughout human ...
(Date:5/27/2015)... 27, 2015 Encision Inc. (OTCQB:ECIA), a medical ... stray electrosurgical burns in minimally invasive surgery, today announced ... fiscal year ended March 31, 2015. The ... a quarterly net loss of $349 thousand, or $(0.03) ... $2.504 million for a net loss of $1.453 million, ...
Breaking Medicine Technology:IGI Laboratories Updates Business Outlook 2IGI Laboratories Updates Business Outlook 3Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 2Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 3Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 4Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 5Encision Reports Fourth Quarter And Fiscal Year 2015 Results 2Encision Reports Fourth Quarter And Fiscal Year 2015 Results 3Encision Reports Fourth Quarter And Fiscal Year 2015 Results 4Encision Reports Fourth Quarter And Fiscal Year 2015 Results 5Encision Reports Fourth Quarter And Fiscal Year 2015 Results 6
... 2011 Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ... clinical and preclinical data highlighting the safety and efficacy ... New Phase 3 data on the ... after augmentation mammoplasty will be presented by Sergio Bergese, ...
... 5, 2011 Xlumena, Inc., a ... endoscopist and endoscopic surgeon, announced today that it ... AXIOS™ Stent and Delivery System (AXIOS). The AXIOS ... translumenal therapy and is indicated for drainage of ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 2Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 3Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 5Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System 2
(Date:5/27/2015)... May 27, 2015 SAN DIEGO, ... Gulfport Mississippi, is the first healthcare provider along ... to chronic care management (CCM). In partnership with ... is introducing RevUp, a new program that enables ... and increase monthly reimbursements. This new, user-friendly program ...
(Date:5/27/2015)... HOUSTON, Tx (PRWEB) May 27, 2015 ... combined germline pharmacogenomic and somatic genomic analysis in personalized ... was published by the American Society of Clinical Oncology ... – June 2 in Chicago. , The molecular and ... The Cancer Genome Atlas (TCGA) database. The study reports ...
(Date:5/27/2015)... On June 5, Plan B [the agency alternative], ... to host Donate Your Break, a public blood drive. ... donor coach outside of 116 W. Illinois (at LaSalle) ... whole blood units is highest for LifeSource, the largest ... requires approximately 1,000 donations per day to maintain an ...
(Date:5/27/2015)... 2015 This is a professional ... the Omega-3 industry. The report provides a basic ... and industry chain structure. The Omega-3 market analysis ... trends, competitive landscape analysis, and key regions development ... Fishing Company, Seadragon Marine Oils, Norwegian Fish Oil, ...
(Date:5/27/2015)... 2015 SonarMD, LLC, recently ... a first-of-its kind, cloud-based algorithmic process for ... chronic gastrointestinal disease. , Developed by noted ... allows physicians to monitor their patients’ health ... of electronic health assessment surveys. Using nationally ...
Breaking Medicine News(10 mins):Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... Roger Seaver, president and CEO of Henry Mayo ... the Hospital Association of Southern California (HASC) for ... leading the board in developing public policies to ... and enhancing communication and consensus on public policy ...
... (UC) researchers have discovered that estrogen receptors are ... brain tumorleading them to believe that anti-estrogen drug ... and improving patients, overall outcome. , This research ... of Endocrinology . , In estrogen-responsive cancerssuch ...
... Marmot, chair of the World Health Organization Commission ... the International Institute for Society and Health at ... Health Lecture Series talk, "Social Determinants of Health: ... Lecture Series is organized by Martin Seligman, University ...
... 17 The Quantum Group, Inc. (NYSE Amex: ... PWeR(TM) (Personal Wellness electronic Record) demonstrations presented at the ... standing room only crowds throughout the 3-day event.Pete Martinez, ... Officer, led the team responsible for the development of ...
... Cross rolls out red carpet for one of its ... the most watched awards show on television, the American ... Barnes, Executive Director of the West Alabama Chapter in ... years ago in Vicksburg (MS). During his tenure with ...
... research? The National Institutes of Health (NIH) wants to ... March 4-6 on behalf of the NIH Office of ... research priorities for the next decade. The meeting begins ... health-care providers, patients, community groups, advocacy groups and other ...
Cached Medicine News:Health News:Henry Mayo CEO Elected Chairman of Hospital Association of Southern California 2Health News:Estrogen found to increase growth of the most common childhood brain tumor 2Health News:The Quantum Group Announces Standing-Room-Only PWeR(TM) Demonstrations at Pri-Med South Expo 2Health News:The Quantum Group Announces Standing-Room-Only PWeR(TM) Demonstrations at Pri-Med South Expo 3Health News:American Red Cross: Meet Our Oscar! 2Health News:American Red Cross: Meet Our Oscar! 3Health News:American Red Cross: Meet Our Oscar! 4Health News:WU hosts public hearing, conference to help NIH prioritize women's health research 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: